MeiraGTx Holdings (MGTX) Interest Coverage Ratio (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Interest Coverage Ratio came in at 4.65 in Q4 2025, up 140.41% YoY from 1.93 in Q4 2024, and up 130.95% on a QoQ basis from 15.02 in Q3 2025.
Powered by 
Analysis
MeiraGTx Holdings (MGTX) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Interest Coverage Ratio data on file, last reported at 4.65 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 140.41% year-over-year to 4.65 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8.36 (up 36.68% YoY) and the FY2025 annual result came in at 0.65, up 40.57% from the prior year.
- Interest Coverage Ratio advanced to 4.65 in Q4 2025, from 15.02 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 4.65 in Q4 2025 to a low of 64.62 in Q4 2021.
- A 5-year average of 15.25 and a median of 13.59 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio slumped 3470.37% — and 2025, when it jumped 140.41%.
- Tracing MGTX's Interest Coverage Ratio over 5 years: stood at 64.62 in 2021, then surged by 52.59% to 30.64 in 2022, then surged by 109.3% to 2.85 in 2023, then plunged by 504.07% to 11.51 in 2024, then jumped by 140.41% to 4.65 in 2025.
- The last three Interest Coverage Ratio figures came in at 4.65 (Q4 2025), 15.02 (Q3 2025), and 12.79 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 69.66 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69.66 |
| Dec 31, 2025 | 5.97 |
| Sep 30, 2025 | -16.48 |
| Jun 30, 2025 | -14.76 |
| Mar 31, 2025 | -13.67 |
| Dec 31, 2024 | -9.23 |
| Sep 30, 2024 | -11.93 |
| Jun 30, 2024 | -14.94 |
| Mar 31, 2024 | -14.39 |
| Dec 31, 2023 | -12.69 |
| Sep 30, 2023 | -9.69 |
| Jun 30, 2023 | -8.58 |
| Mar 31, 2023 | -10.38 |
| Dec 31, 2022 | -14.18 |
| Sep 30, 2022 | -12.05 |
| Jun 30, 2022 | -289.73 |
| Mar 31, 2022 | -373.17 |
| Dec 31, 2021 | -64.62 |
| Sep 30, 2021 | -382.24 |
| Jun 30, 2021 | -401.63 |